

CATALYST PHARMACEUTICAL PARTNERS, INC.  
Form 8-K  
March 05, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**  
**FORM 8-K**  
**CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF**  
**THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of Earliest Event Reported): March 5, 2015

**CATALYST PHARMACEUTICAL PARTNERS, INC.**

(Exact Name Of Registrant As Specified In Its Charter)

**Delaware**  
(State or other jurisdiction of  
incorporation)

**001-33057**  
(Commission File Number)

**76-0837053**  
(I.R.S. Employer  
Identification No.)

**355 Alhambra Circle**

**Suite 1500**

**Coral Gables, Florida**  
(Address of principal executive offices)

**33134**  
(Zip Code)

Registrant's telephone number, including area code:  
**Not Applicable**

(305) 529-2522

Former Name or Former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events**

On March 5, 2015, the Company issued a press release reporting that the U.S. Food and Drug Administration (FDA) has granted the Company orphan drug designation for Firdapse for the treatment of Congenital Myasthenic Syndromes.

Additionally, the Company announced that it has received the official minutes from the FDA reporting on the discussions at its formal pre-new drug application (NDA) meeting held earlier this year, and that the minutes confirm the information about the results of the meeting previously reported by the Company in its Form 8-K filed on February 2, 2015.

A copy of the Company's press release is attached as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

99.1 Press release issued by the Company on March 5, 2015.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Catalyst Pharmaceutical Partners, Inc.**

By: /s/ Alicia Grande  
Alicia Grande  
Vice President, Treasurer and CFO

Dated: March 5, 2015